Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies

Journal of Virology

Volumn 76, Issue 18, 2002, Pages 9253-9259

  Mansky, Louis M ^a   Pearl, Dennis K ^a   Gajary, Lisa C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; DRUG ACCUMULATION; DRUG EFFECT; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION RATE; PATIENT COMPLIANCE; POPULATION DYNAMICS; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GENETIC VECTORS; HELA CELLS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROXYUREA; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0036721138     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.18.9253-9259.2002     Document Type: Article

References (42)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
3. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals
4. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
5. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism
6. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
7. Genetic drift and within-host metapopulation dynamics of HIV-1 infection
8. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
9. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
10. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
11. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
12. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
13. Genetic consequences of packaging two RNA genomes in one retroviral particle: Pseudodiploidy and high rate of genetic recombination
14. A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction
15. The antiretrovirus drug 3′-azido-3′-deoxythymidine increases the retrovirus mutation rate
16. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate
17. Emergence of multidideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy
18. Clinical significance of drug resistance in HIV-1 infection
19. Equilibrium and kinetic studies of Escherichia coli lac repressor-inducer interactions
20. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population
21. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
22. Forward mutation rate of human immunodeficiency virus type 1 in a T-lymphoid cell line
23. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene
24. Retroviral-vector-mediated gene transfer
25. 3′-azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1
26. Interaction of human immunodeficiency virus type 1 Vpr with the HHR23A DNA repair protein does not correlate with multiple biological functions of Vpr
27. The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate
28. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase
29. Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus
30. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
31. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
32. V3 loop of the human immunodeficiency virus type 1 Env protein: Interpreting sequence variability
33. 5-azacytidine and RNA secondary structure increase the retrovirus mutation rate
34. Incidence and impact of resistance against approved antiretroviral drugs
35. Reverse transcriptase fidelity and HIV-1 variation
36. Interactions between deoxyribonucleotide and DNA synthesis
37. HIV chemotherapy
38. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
39. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
40. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
41. Consequences of the depletion of cellular deoxynucleoide triphosphate pools on the excision-repair process in cultured human fibroblast
42. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia